MAP2K1 and breast cancer: The effects of similar combination strategy have also been reported in two other studies: MEK1/2i with docetaxel (a microtubule poison) reduced mammary tumor growth in vivo (Yacoub et al, 2006), and a MEK1/2‐PLK1 inhibition caused regression of NRAS mutant melanoma xenografts (Posch et al, 2015).